{"id":"bgf-mdi-pt010","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Dysphonia"}]},"_chembl":{"chemblId":"CHEMBL1588467","moleculeType":"Small molecule","molecularWeight":"332.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The formulation combines budesonide (ICS) to suppress airway inflammation, formoterol (LABA) to provide rapid and sustained bronchodilation via beta-2 receptor agonism, and glycopyrronium (LAMA) to provide additional bronchodilation through muscarinic receptor antagonism. This triple therapy addresses multiple pathophysiologic mechanisms in COPD to improve lung function and reduce exacerbations.","oneSentence":"BGF MDI is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation in chronic obstructive pulmonary disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:40.178Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"}]},"trialDetails":[{"nctId":"NCT04609878","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-15","conditions":"Asthma","enrollment":2274},{"nctId":"NCT04609904","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-01","conditions":"Asthma","enrollment":2187},{"nctId":"NCT02536508","phase":"PHASE3","title":"Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-08-10","conditions":"COPD","enrollment":627},{"nctId":"NCT03906045","phase":"PHASE1","title":"A Scintigraphy Study of PT010 in COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-04-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":18},{"nctId":"NCT02465567","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-06-30","conditions":"COPD","enrollment":8588},{"nctId":"NCT03075267","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2017-04-17","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":96},{"nctId":"NCT02497001","phase":"PHASE3","title":"A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-08-10","conditions":"COPD","enrollment":1902},{"nctId":"NCT03311373","phase":"PHASE1","title":"A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2017-10-17","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":56},{"nctId":"NCT03262012","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-08-09","conditions":"COPD","enrollment":416},{"nctId":"NCT03740373","phase":"PHASE1","title":"A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-09-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":10},{"nctId":"NCT03081247","phase":"PHASE3","title":"To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","status":"WITHDRAWN","sponsor":"Pearl Therapeutics, Inc.","startDate":"2018-04-16","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT02197975","phase":"PHASE1","title":"Randomized, Crossover Safety and Pharmacokinetics Study of PT010","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2014-08","conditions":"COPD","enrollment":20},{"nctId":"NCT01980615","phase":"PHASE1","title":"Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-11","conditions":"Healthy Volunteers","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BGF"],"phase":"phase_3","status":"active","brandName":"BGF MDI (PT010)","genericName":"BGF MDI (PT010)","companyName":"Pearl Therapeutics, Inc.","companyId":"pearl-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BGF MDI is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}